Efalizumab therapy for atopic dermatitis causes marked increases in circulating effector memory CD4+ T cells that express cutaneous lymphocyte antigen

Erin G. Harper, Eric Simpson, Rodd H. Takiguchi, Miranda D. Boyd, Stephen E. Kurtz, Antony C. Bakke, Andrew Blauvelt

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Efalizumab is an mAb directed against CD11a, a molecule involved in T-cell activation and extravasation from blood into tissue. Ten patients with severe atopic dermatitis were treated with efalizumab for 84 days, and peripheral blood mononuclear cells were analyzed for expression of activation and adhesion markers. Efalizumab treatment led to decreases in CD11a mean fluorescence intensity (MFI) on naive, central memory, and effector memory CD4+ and CD8+ T cell subsets. MFI for CD18 was decreased in both CD4+ and CD8+ T cells. Percentages of cells positive for cutaneous lymphocyte antigen (CLA) were increased fourfold in all CD4+ and CD8+ T cell subsets. Increases in the percentages of CD4+ and CD8+ T cells expressing β7 and CD49d were also observed. No significant changes were observed in the percentages of CD4+ and CD8+ T cells that produced either IFN-γ or IL-4. In summary, efalizumab treatment resulted in (i) decreases in CD11a and CD18 expression in all circulating T-cell subsets and (ii) increases in the percentages of blood T cells expressing tissue homing markers (CLA, β7, CD49d). These data suggest that blockade of T-cell extravasation into tissue is the major pathway by which efalizumab leads to improvement in cutaneous inflammation.

Original languageEnglish (US)
Pages (from-to)1173-1181
Number of pages9
JournalJournal of Investigative Dermatology
Volume128
Issue number5
DOIs
StatePublished - May 2008

Fingerprint

T-cells
Lymphocytes
Atopic Dermatitis
T-Lymphocytes
Antigens
Data storage equipment
Skin
T-Lymphocyte Subsets
Integrin alpha4
Blood Cells
Blood
Therapeutics
Fluorescence
Tissue
Chemical activation
Interleukin-4
efalizumab
Inflammation
Adhesion
Molecules

ASJC Scopus subject areas

  • Dermatology

Cite this

Efalizumab therapy for atopic dermatitis causes marked increases in circulating effector memory CD4+ T cells that express cutaneous lymphocyte antigen. / Harper, Erin G.; Simpson, Eric; Takiguchi, Rodd H.; Boyd, Miranda D.; Kurtz, Stephen E.; Bakke, Antony C.; Blauvelt, Andrew.

In: Journal of Investigative Dermatology, Vol. 128, No. 5, 05.2008, p. 1173-1181.

Research output: Contribution to journalArticle

@article{8205c5b12d40412ba826f08523559065,
title = "Efalizumab therapy for atopic dermatitis causes marked increases in circulating effector memory CD4+ T cells that express cutaneous lymphocyte antigen",
abstract = "Efalizumab is an mAb directed against CD11a, a molecule involved in T-cell activation and extravasation from blood into tissue. Ten patients with severe atopic dermatitis were treated with efalizumab for 84 days, and peripheral blood mononuclear cells were analyzed for expression of activation and adhesion markers. Efalizumab treatment led to decreases in CD11a mean fluorescence intensity (MFI) on naive, central memory, and effector memory CD4+ and CD8+ T cell subsets. MFI for CD18 was decreased in both CD4+ and CD8+ T cells. Percentages of cells positive for cutaneous lymphocyte antigen (CLA) were increased fourfold in all CD4+ and CD8+ T cell subsets. Increases in the percentages of CD4+ and CD8+ T cells expressing β7 and CD49d were also observed. No significant changes were observed in the percentages of CD4+ and CD8+ T cells that produced either IFN-γ or IL-4. In summary, efalizumab treatment resulted in (i) decreases in CD11a and CD18 expression in all circulating T-cell subsets and (ii) increases in the percentages of blood T cells expressing tissue homing markers (CLA, β7, CD49d). These data suggest that blockade of T-cell extravasation into tissue is the major pathway by which efalizumab leads to improvement in cutaneous inflammation.",
author = "Harper, {Erin G.} and Eric Simpson and Takiguchi, {Rodd H.} and Boyd, {Miranda D.} and Kurtz, {Stephen E.} and Bakke, {Antony C.} and Andrew Blauvelt",
year = "2008",
month = "5",
doi = "10.1038/sj.jid.5701169",
language = "English (US)",
volume = "128",
pages = "1173--1181",
journal = "Journal of Investigative Dermatology",
issn = "0022-202X",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - Efalizumab therapy for atopic dermatitis causes marked increases in circulating effector memory CD4+ T cells that express cutaneous lymphocyte antigen

AU - Harper, Erin G.

AU - Simpson, Eric

AU - Takiguchi, Rodd H.

AU - Boyd, Miranda D.

AU - Kurtz, Stephen E.

AU - Bakke, Antony C.

AU - Blauvelt, Andrew

PY - 2008/5

Y1 - 2008/5

N2 - Efalizumab is an mAb directed against CD11a, a molecule involved in T-cell activation and extravasation from blood into tissue. Ten patients with severe atopic dermatitis were treated with efalizumab for 84 days, and peripheral blood mononuclear cells were analyzed for expression of activation and adhesion markers. Efalizumab treatment led to decreases in CD11a mean fluorescence intensity (MFI) on naive, central memory, and effector memory CD4+ and CD8+ T cell subsets. MFI for CD18 was decreased in both CD4+ and CD8+ T cells. Percentages of cells positive for cutaneous lymphocyte antigen (CLA) were increased fourfold in all CD4+ and CD8+ T cell subsets. Increases in the percentages of CD4+ and CD8+ T cells expressing β7 and CD49d were also observed. No significant changes were observed in the percentages of CD4+ and CD8+ T cells that produced either IFN-γ or IL-4. In summary, efalizumab treatment resulted in (i) decreases in CD11a and CD18 expression in all circulating T-cell subsets and (ii) increases in the percentages of blood T cells expressing tissue homing markers (CLA, β7, CD49d). These data suggest that blockade of T-cell extravasation into tissue is the major pathway by which efalizumab leads to improvement in cutaneous inflammation.

AB - Efalizumab is an mAb directed against CD11a, a molecule involved in T-cell activation and extravasation from blood into tissue. Ten patients with severe atopic dermatitis were treated with efalizumab for 84 days, and peripheral blood mononuclear cells were analyzed for expression of activation and adhesion markers. Efalizumab treatment led to decreases in CD11a mean fluorescence intensity (MFI) on naive, central memory, and effector memory CD4+ and CD8+ T cell subsets. MFI for CD18 was decreased in both CD4+ and CD8+ T cells. Percentages of cells positive for cutaneous lymphocyte antigen (CLA) were increased fourfold in all CD4+ and CD8+ T cell subsets. Increases in the percentages of CD4+ and CD8+ T cells expressing β7 and CD49d were also observed. No significant changes were observed in the percentages of CD4+ and CD8+ T cells that produced either IFN-γ or IL-4. In summary, efalizumab treatment resulted in (i) decreases in CD11a and CD18 expression in all circulating T-cell subsets and (ii) increases in the percentages of blood T cells expressing tissue homing markers (CLA, β7, CD49d). These data suggest that blockade of T-cell extravasation into tissue is the major pathway by which efalizumab leads to improvement in cutaneous inflammation.

UR - http://www.scopus.com/inward/record.url?scp=42149162298&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42149162298&partnerID=8YFLogxK

U2 - 10.1038/sj.jid.5701169

DO - 10.1038/sj.jid.5701169

M3 - Article

VL - 128

SP - 1173

EP - 1181

JO - Journal of Investigative Dermatology

JF - Journal of Investigative Dermatology

SN - 0022-202X

IS - 5

ER -